The label contains complete use information, including cautions and warnings. Always read, follow and understand the label and use directions.

PULMOTIL^® AC

IMPORTANT SAFETY INFORMATION:

Before using this product, it is important to read the entire product insert, including the boxed human warning.

WARNING: Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin. Avoid direct skin and eye contact. In case of human exposure, call 1-800-722-0987 and consult a physician immediately.

• Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

• For use only in swine. Not for injection. Injection of tilmicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.
• Swine intended for human consumption must not be slaughtered within 7 days of treatment.
• Always treat the fewest number of animals necessary to control a respiratory disease outbreak. Prescriptions shall not be refilled.
• Concurrent use of Pulmotil AC and another macrolide by any route, or use of another macrolide immediately following this use of Pulmotil AC is not advised.
• Ensure that pigs have continuous access to medicated water during the treatment period. Monitor pigs for signs of water refusal and dehydration while being treated.

INDICATIONS:

• For the control of swine respiratory disease associated with Pasteurella multocida and Haemophilus parasuis in groups of swine in building where a respiratory disease outbreak is diagnosed.
• For the control of swine respiratory disease associated with Mycoplasma hyopneumoniae in the presence of porcine reproductive and respiratory syndrome virus (PRRSv) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

DOSAGE AND ADMINISTRATION:

• Must be diluted before administration to animals.
• Include in the drinking water to provide a concentration of 200 mg tilmicosin per liter (200 ppm).
• One 960 ml bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs.
• The medicated water should be administered for (5) five consecutive days.
• Use within 24 hours of mixing with water.
• Do not use rusty containers for medicated water as they may affect product integrity.
• When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 ml) of Pulmotil AC per 2.5 gallons of stock solution.

INCREXXA^TM

INDICATIONS:

• Increxxa Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

DIRECTIONS FOR USE:

• Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

IMPORTANT SAFETY INFORMATION:

• CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
• WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.
• Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.
• The effects of Increxxa on porcine reproductive performance, pregnancy, and lactation have not been determined.
• Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
• Store below 25°C (77°F), with excursions up to 40°C (104°F).
• 100 mL: Use within 2 months of first puncture and puncture a maximum of 67 times. If more than 67 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.
• 250 mL and 500 mL: Use within 2 months of first puncture and puncture a maximum of 100 times. If more than 100 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.

PREVACENT^® PRRS

INDICATIONS:

• This product has been shown to be effective for the vaccination of healthy pigs 2 weeks of age or older against PRRS respiratory disease; and against reproductive disease when vaccinated 6 weeks prior to breeding.
• The duration of immunity against respiratory disease is at least 26 weeks.
• The duration of immunity against reproductive disease has not been established. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.
• Safety of this product has been demonstrated when sows or gilts are vaccinated prior to breeding or at any stage of pregnancy.
• Vaccine virus may be shed and transmitted to other populations of swine in contact with vaccinated swine.
• The duration of potential vaccine virus transmission may vary.
• Use of the vaccine in herds intended to remain PRRS virus seronegative is contraindicated.
• Introduction of vaccinated pigs into herds intended to remain PRRS virus seronegative is contraindicated.

DOSAGE AND ADMINISTRATION:

• Rehydrate with the accompanying sterile diluent.
• Shake well and draw back into the syringe the required amount.
• Administer 1 mL intramuscularly.
• The need for annual booster vaccinations has not been established for this product; consultation with a veterinarian is recommended.

IMPORTANT SAFETY INFORMATION

PRECAUTIONS:

• Store at 2°- 8°C (35°- 46°F). DO NOT FREEZE.
• Use entire contents when first opened.
• Do not mix with other products, except as specified on this label. In case of human exposure, contact a physician.
• Do not vaccinate within 21 days before slaughter.
• Inactivate unused contents before disposal.
• Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine. Contains gentamicin as preservative.

SKYCIS^®

INDICATIONS:

• For increased rate of weight gain in growing-finishing swine when fed for at least 4 weeks.
• For increased rate of weight gain and improved feed efficiency in growing-finishing swine when fed for at least 4 weeks.

DIRECTIONS FOR USE:

• For increased rate of weight gain in growing-finishing swine when fed for at least 4 weeks:
  • Feed 13.6 to 27.2 g/ton (15 ppm to 30 ppm) in a Type C Medicated feed.
• For increased rate of weight gain and improved feed efficiency in growing-finishing swine when fed for at least 4 weeks:
  • Feed 18.1 to 27.2 g/ton (20 ppm to 30 ppm) in a Type C Medicated feed.
• No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 15 ppm (13.6 g/ton).

IMPORTANT SAFETY INFORMATION

CAUTION:

• Do not allow adult turkeys, horses or other equines access to narasin formulations. Ingestion of narasin by these species has been fatal. Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals.
• Swine being fed with Skycis (narasin) should not have access to feeds containing pleuromutilins (e.g. tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

WARNING: No withdrawal period is required when used according to the label.

• Store at or below 25° C (77°F). Excursions permitted to 37° C (99°F).

Communicate Skycis inclusions in feed to the full production system prior to use. Proper training, formulations, mixing and concentration levels are important to successfully implement Skycis.